Mainz Biomed (MYNZ) Provides Year-End 2022 Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Mainz Biomed (MYNZ) Provides Year-End 2022 Update

Mainz Biomed Provides Year-End 2022 Corporate Review

January 3, 2023 3:01 AM EST

BERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022.

Key Commercial, Operational and Product Development Highlights

Launched U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomeds mRNA biomarkers in identifying Advance Adenomas (AA), a type of pre-cancerous polyp often attributed to... More